Skip to main content
Equibles
RAPP logo

RAPP · Rapport Therapeutics, Inc. · Metrics

Track RAPP — free

Use RAPP with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research RAPP.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$22.50 -5.04 (-18.30%) At close · Oct 28
Russell 2000 member Rebalance outlook locked
Market Cap
$1.12B
Shares
47.98M
Volume · Oct 28 5.96M Avg daily vol (3M) 637.16K

RAPP metrics

61 of 122 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$22.50
Market cap
$1.12B

Price action

20 metrics
Price change (1W)
-10.2%
Price change (30D)
-31.9%
Price change (3M)
-45.0%
Price change (6M)
-31.8%
Price change (YTD)
-25.8%
Price change (1Y)
-22.3%
Trailing year
Price change (5Y)
—
52-week high
$52.50
52-week low
$22.50
Change from 52-week high
-57.1%
Change from 52-week low
+0.0%
Annualized volatility
61.8%
Annualized volatility (3M)
75.3%
Beta
1.2
RSI (14D)
29.2
Price vs SMA 50
-40.3%
Price vs SMA 200
-36.9%
Avg volume (3M)
637,160
Relative volume
9.4
Average dollar volume
$21.16M

Company

3 metrics
Sector
Healthcare
Industry
Biotechnology
Shares outstanding
47.98M

Valuation

12 metrics
P / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
—
EV / EBITDA
—
EV / EBIT
—
P / sales
—
P / book
2.6
reciprocal yield 37.8%
FCF yield
-8.7%
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
—
Earnings yield
-12.3%

Historical valuation

8 metrics
P / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
—
EV / revenue historical average (5Y)
—
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
—
Last earnings
2026-10-20

Profitability

9 metrics
Gross margin
—
Operating margin
—
Trailing 12 months
Net margin
—
Gross profit (TTM)
—
Operating profit (TTM)
−$153.52M
Net income (TTM)
−$137.16M
Trailing 12 months
Diluted EPS (TTM)
$-3.04
FCF margin
—
Effective tax rate
—

Per share

11 metrics
Revenue per diluted share (TTM)
—
Gross profit per diluted share (TTM)
—
Operating profit per diluted share (TTM)
—
EBITDA per diluted share (TTM)
—
Net income per diluted share (TTM)
—
Operating cash flow per diluted share (TTM)
—
Free cash flow per diluted share (TTM)
—
Capital expenditures per diluted share (TTM)
—
R&D per diluted share (TTM)
—
Stock compensation per diluted share (TTM)
—
Book value per share
$10.15

Growth

11 metrics
Revenue growth YoY
—
Year over year
Net income growth YoY
—
Revenue (TTM)
—
Trailing 12 months
EPS growth YoY
—
Shares change YoY
+33.9%
Year over year · more shares
Revenue CAGR (3Y)
—
Revenue CAGR (5Y)
—
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—

Quality

14 metrics
Return on equity
-32.4%
Return on assets
-29.9%
Debt / equity
0.0
Current ratio
15.7
EBITDA (TTM)
−$152.56M
Free cash flow (TTM)
−$97.15M
Quick ratio
15.7
Interest coverage
—
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
$436.08M
Latest balance sheet
Cash & equivalents
$63.61M
Total assets
$458.98M
Total debt
$0

Cash flow & spend

7 metrics
Operating cash flow (TTM)
−$96.68M
Capital expenditures (TTM)
$467,000
R&D (TTM)
$136.67M
SG&A (TTM)
—
Stock compensation (TTM)
$24.59M
R&D / revenue
—
Stock compensation / revenue
—

Ownership (13F)

9 metrics
13F filers
160
13F filer change QoQ
+13
Institutional ownership
106.9%
Conviction holders (share of 13F filers)
4.4%
Crowding (high-turnover and private-fund holders)
—
Private-fund adviser ownership
—
Active holders' share change QoQ
-1.9%
Holder tenure
7.2
Price vs estimated holder cost
+80.3%

Ownership (registered funds)

1 metrics
Index-fund ownership
9.5%

Short interest

3 metrics
Short interest
6.4%
Latest settlement · 11.8 days to cover
Days to cover
11.8d
Short-squeeze score
56 / 100

Insider activity

2 metrics
Net insider buying (90D)
−$5.26M
Insider-sentiment score
95 / 100

Risk flags

1 metrics
Going concern
—
Key facts CIK 2012593 CUSIP 75383L102 13F (30d) 25 filings 25 filers Visit website Investor relations